1960: First Birth Control Pill

On This Day in Health: May 9, 1960

On May 9, 1960, the U.S. Food and Drug Administration conditionally approved Enovid for use as an oral contraceptive. The decision became a landmark in reproductive medicine, opening the way for the first commercially produced birth control pill. Manufactured by G. D. Searle, Enovid combined synthetic hormones to prevent pregnancy. The May decision should be distinguished from the subsequent steps that brought the contraceptive to the market. Its importance was nonetheless clear: a medication could give women a new means of controlling the timing of pregnancy, with consequences extending from individual healthcare decisions to family life, education and employment.

The development followed years of scientific work and financial support. Margaret Sanger advocated for a practical oral contraceptive, while Katherine McCormick supplied crucial funding. Gregory Pincus and John Rock were central to the research program. Clinical testing explored whether hormones could reliably suppress ovulation, translating knowledge of the reproductive cycle into a medicine intended for repeated use. Early tablets were dispensed in vials, before the familiar calendar-style packages that later helped users track doses. The Smithsonian's surviving trial material illustrates that development stage: the product and its packaging were still being refined as researchers studied effectiveness, dosage and tolerability.

The innovation also raised issues that could not be settled by contraceptive effectiveness alone. Women taking the pill were often otherwise healthy and might use it for long periods, making clear information about benefits and risks especially important. The FDA's historical account notes that Enovid was linked to an increased risk of venous thrombosis after its introduction. Patient information became part of the regulatory response. The development program also involved vulnerable populations and research methods that later contributed to calls for stronger protections in clinical trials. Those concerns belong within the history of the milestone, alongside the scientific achievement and the expanded opportunities for family planning.

Approval did not instantly create equal access or end disputes over contraception. A prescription medicine depended on contact with healthcare services, and the wider meaning of the pill was shaped by social attitudes and institutions as well as pharmacology. Its introduction changed the relationship between many women and their doctors by making ongoing contraceptive management a part of routine care. May 9 is therefore remembered as both a medical and social turning point. The anniversary is most accurate when it names the conditional decision, recognizes the people and research behind it, and includes the subsequent lessons about safety and informed participation. The history of the pill joins greater reproductive choice with the continuing responsibility to explain medical risks clearly.